To assess whether 5-year overall survival (OS) of squamous cell carcinoma of the penis (SCCP) patients differs from age-matched male population-based controls.
We relied on the Surveillance Epidemiology and End Results database (2004-2018) to identify newly diagnosed (2004-2013) SCCP patients. For each case, we simulated an age-matched control (Monte Carlo simulation), relying on the Social Security Administration (SSA) Life Tables with 5 years of follow-up. We compared OS between SCCP patients and population-based controls in a stage-specific fashion. Smoothed cumulative incidence plots displayed cancer-specific mortality (CSM) versus other-cause mortality (OCM).
Of 2282 SCCP patients, the stage distribution was as follows: stage I 976 (43%) versus stage II 826 (36%) versus stage III 302 (13%) versus stage IV 178 (8%). At 5 years, OS of SCCP patients versus age-matched population-based controls was as follows: stage I 63% versus 80% (Δ = 17%), stage II 50% versus 80% (Δ = 30%), stage III 39% versus 84% (Δ = 45%), stage IV 26% versus 87% (Δ = 61%). At 5 years, CSM versus OCM in SCCP patients according to stage was as follows: stage I 12% versus 24%, stage II 22% versus 28%, stage III 47% versus 14%, and stage IV 60% versus 14%.
SCCP patients exhibit worse OS across all stages. The difference in OS at 5 years between SCCP and age-matched male population-based controls ranged from 17% to 61%. At 5 years, CSM accounted for 12% to 60% of all deaths, across all stages.
International journal of urology : official journal of the Japanese Urological Association. 2023 Nov 28 [Epub ahead of print]
Lukas Scheipner, Stefano Tappero, Mattia Luca Piccinelli, Francesco Barletta, Cristina Cano Garcia, Reha-Baris Incesu, Simone Morra, Zhe Tian, Fred Saad, Shahrokh F Shariat, Carlo Terrone, Ottavio De Cobelli, Alberto Briganti, Felix K H Chun, Derya Tilki, Nicola Longo, Maximilian Seles, Sascha Ahyai, Pierre I Karakiewicz
Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montréal Health Center, Montréal, Québec, Canada., Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Department of Urology, IRCCS Policlinico San Martino, Genova, Italy., Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy., Soldera Prostate Cancer Lab, Unit of Urology/Division of Oncology, Gianfranco, IRCCS San Raffaele Scientific Institute, Milan, Italy., Vita-Salute San Raffaele University, Milan, Italy., Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany., Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany., Department of Urology, Medical University of Graz, Graz, Austria.